The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
40
No.
39
October 17, 2014
- Indiana to Close Proton Beam Facility Amid Nationwide Building Boom
- Conversation with The Cancer Letter: IU’s Loehrer Discusses “Business Decision” To Close Bloomington Proton Beam Center
- Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin
- ASCO Endorses Guideline for Molecular Testing
- IARC Publishes Fourth Edition of European Code Against Cancer
- Funding Opportunity: Stand Up To Cancer Canada to Fund Two Dream Teams
- In Brief: Francis Giles named deputy director of Lurie Cancer Center
- Drugs and Targets: FDA approves Velcade in mantle cell lymphoma
TCL
Vol.
40
No.
40
October 24, 2014
- 40 Years Later: Doctor and Patient Reflect on the Cure
- Conversation with The Cancer Letter: Einhorn: “I Still Harbor Hope For Similar Success Stories”
- Caris Life Sciences Lays Off Estimated 20 Percent of Staff
- HRSA: Discounts Owed on Some Orphan Drug Uses
- Cancer Support Community Reports on Patient Experiences
- Institute of Medicine Elects 80 New Members
- In Brief: Benjamin Neel named director of NYU Cancer Center
- Drugs and Targets: EU approves Imbruvica in MCL, CLL
TCL
Vol.
40
No.
41
October 31, 2014
- How Elite Institutions Were Affected By A Decade of Constricted Funding
- The Impact of Triple Calamities: Flat Funding, the End of ARRA, and a Dramatic Loss of Purchasing Power
- Guest Editorial: The Academic Difference: George Weiner On How America’s Cancer Centers Are More Valuable Than Ever
- Bennett, Federal Prosecutors Reach $475,000 Settlement
- Funding Opportunity: Leukemia & Lymphoma Society Launches Myeloid Program
- In Brief: City of Hope launches Hematologic Malignancies and Stem Cell Transplantation Institute
- Drugs and Targets: FDA extends Lymphoseek label to include mapping in solid tumors
CCL
Vol.
37
No.
10
October 31, 2014
- Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial
- Cobimetinib-Zelboraf Therapy Increases OS In BRAF V600 Mutation-Positive Disease
- FDA Approves Velcade Injection In Mantle Cell Lymphoma
- Phase II Study of Veliparib Improves PFS by 35 Percent
- Tafinlar Subgroup Data Shows Median OS of 20 Months
- Study: Angiopoietin-2 Levels May Predict Lenvatinib Response
- Afatinib Delays Tumor Growth In LUX-Head and Neck 1 Study
- Zytiga and Prednisone Extends Overall Survival in mCRPC Trial
- Anamorelin Increases Body Mass In Two Global Phase III Trials
- NCI CTEP-Approved Trials For the Month of October
TCL
Vol.
40
No.
42
November 07, 2014
TCL
Vol.
40
No.
43
November 14, 2014
- CMS Inserts Unprecedented Conditions Into Medicare Coverage of Lung Screening
- Brawley: CMS Got it Right in Lung Cancer Screening Decision
- FDA News: Avastin Combination Approved In Recurrent Ovarian Cancer
- CPRIT Sets Funding Priorities For Rare and Pediatric Cancers
- CDC: About 8 Million Women Skipped Cervical Cancer Screening in the Past 5 Years
- 2015 Breakthrough Prize Winners Announced at Gala
- In Brief: Susan O’Brien to move to UC Irvine Health
TCL
Vol.
40
No.
44
November 21, 2014
- As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study
- Page 2: The Debate Over Brigham’s Containment Bag Study
- Conversation with TCL:Demetri: Morcellation Worsens Outcomes In Patients with Undiagnosed Cancers
- CPRIT Awards 32 Grants
- ASCO Proposes Principles For Future Debate on Medicaid
- Obituary: Connie Curran, 67, C-Change Executive Director
- FDA News: FDA Taking Comments on “First Generic” ANDA Process
- In Brief: D. Gary Gilliland Named President and Director of Fred Hutchinson Cancer Research Center
TCL
Vol.
40
No.
Nov 26 special report
November 26, 2014